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Incontinence, hematuria, voiding frequency and pain during voiding are possible side effects
of radiotherapy among patients treated for prostate cancer. The objective of this study was
to develop multivariable NTCP models for these side effects.
Material and methods
This prospective cohort study was composed of 243 patients with localized or locally
advanced prostate cancer (stage T1-3). Genito-urinary (GU) toxicity was assessed using a
standardized follow-up program. The GU toxicity endpoints were scored using the Common
Terminology Criteria for Adverse Events version 3.0 (CTCAE 3.0) scoring system. The full
bladder and different anatomical subregions within the bladder were delineated. A least
absolute shrinkage and selection operator (LASSO) logistic regression analysis was used to
analyze dose volume effects on the four individual endpoints.
Results
In the univariable analysis, urinary incontinence was significantly associated with dose distri-
butions in the trigone (V55-V75, mean). Hematuria was significantly associated with the
bladder wall dose (V40-V75, mean), bladder dose (V70-V75), cardiovascular disease and
anticoagulants use. Pain during urinating was associated with the dose to the trigone (V50-
V75, mean) and with trans transurethral resection of the prostate (TURP). In the final multi-
variable model urinary incontinence was associated with the mean dose of the trigone.
Hematuria was associated with bladder wall dose (V75) and cardiovascular disease, while
pain during urinating was associated with trigone dose (V75) and TURP. No significant
associations were found for increase in voiding frequency.
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Conclusions
Radiation-induced urinary side effects are associated with dose distributions to different
organs as risk. Given the dose effect relationships found, decreasing the dose to the trigone
and bladder wall may reduce the incidence of incontinence, pain during voiding and hematu-
ria, respectively.
Introduction
The introduction of intensity modulated radiotherapy (IMRT) and dose escalation has resulted
in increased biochemical relapse free survival for localized prostate cancer [1]. Despite this
increase in tumor control, adjacent organs at risk (OAR) are exposed to high doses that may
lead to increased rates of radiation-induced side effects that have an impact on quality of life
[2].
To achieve a reduction in side effect rates by adjusting radiotherapy planning, knowledge of
the association between complication risk and dose distribution parameters is required.
Traditionally, a distinction is made between gastrointestinal (GI) and genitourinary (GU)
side effects. Dose to specific substructures within and around the anorectum are associated
with specific gastrointestinal side effects [3]. Previous studies on genitourinary side effects
showed the dose to the bladder was associated with urinary toxicity among patients treated
with external beam radiotherapy [4] [5]. Interestingly, dose to the trigone was associated with
genitourinary side effects among patients treated with brachytherapy [6,7].
In the vast majority of studies on GU side effects after radiotherapy, toxicity is typically
scored as a single cumulative endpoint for all GU side effects taken together, rather than a
single score for incontinence, hematuria, pain and increased voiding frequency individually.
Presently no multivariable models exists on dose to regions within the bladder and specific late
side effects among IMRT treated prostate cancer patients. Therefore, the main objective of this
study was to develop multivariable NTCP (Normal Tissue Complication Probability) models
for urinary incontinence, hematuria, pain and increased voiding frequency taking into account




This prospective cohort study was previously described in [3] and was composed of 243
patients with prostate cancer confined to the prostatic capsule (stage T1-3). All patients were
treated with radiotherapy between 2005 and 2009. The minimal follow up of patients alive was
3 years. Radiotherapy was delivered using linear accelerators with 6 MV photons by intensity
modulated radiotherapy (IMRT). Patients were treated 5 times a week to a total dose of 78 Gy
on the planning target volume (PTV), using 2 Gy per fraction. In the current patient cohort,
no pelvic lymph nodes were irradiated as part of the treatment. Setup accuracy was verified
during delivery by matching bony anatomy or implanted fiducial markers. Most patients with
locally advanced prostate cancer received adjuvant hormonal treatment (Table 1). Diabetes
was defined as “use of hypoglycemic drugs”, smoking was defined as “any kind of smoking his-
tory”. These patient characteristics were retrospectively assessed from detailed patient charts.
Prediction of side effects after prostate radiotherapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0197757 July 17, 2018 2 / 12
the data management department at
rtdatamanagement@rt.umcg.nl.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
For the purpose of the current analysis, only patients biochemically failure free at three years
after treatment were eligible for this study.
Ethics statement
All patients were subjected to a prospective data registration program in which complications
and treatment results in terms of local control and survival are prospectively assessed. This is
done within the framework of routine clinical practice in which outcome and complications
are systemically scored as part of a quality assurance program. All data obtained and used for
this study has been anonymized.
The (Dutch) Medical Research Involving Human Subjects Act is not applicable to data col-
lection as part of routine clinical practice and use of these data for scientific papers regarding
the quality assurance program. Only research that is within the scope of the Medical Research
Involving Human Subjects Act needs approval from an (accredited) ethics committee. There-
fore, the hospital ethics committee (the Medisch Ethische Toetsingscommissie; METc) con-
cluded that data collection by this program is regarded as part of routine patient care and
granted us a waiver from needing ethical approval for the conduct of this study.
In the Netherlands a patient of course has to give his/her consent for the collection of the
extra data on behalf of the quality assurance program and the use of these data for scientific
Table 1. Patient and treatment characteristics.
Number of patients %
Age
 70 years 139 57














Adjuvant hormonal therapy 104 43
Fiducial markers 73 30
Pre-treatment related factors
History of diabetes 29 12
Smoking 77 32
History of cardiovascular disease 82 34
History of abdominal surgery 90 37
Anticoagulants use 63 26
TURP 52 21
PSA: Prostate-specific antigen
TURP:transurethral resection of the prostate
https://doi.org/10.1371/journal.pone.0197757.t001
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papers regarding the quality assurance program. However, according to Dutch legislation,
consent is free of form, and verbal consent is sufficient. Therefore, patients were asked to par-
ticipate in this quality assurance program and asked for permission to use their data for the
program and scientific papers regarding the program. Refusal of participation was recorded in
their medical record.
Target and organ at risk delineation
Three Planning Target Volumes (PTV) were defined: the PTV46 included the prostate and
vesicles, the PTV70 included the prostate and the basis of the vesicles and the PTV78 included
the prostate only.
The full bladder was delineated as part of the treatment planning. Patients were instructed
to urinate and drink half a liter of water one hour prior to radiotherapy. The bladder wall was
created using an inner ring within the full bladder of 3.3mm [8]. The trigone was defined as
the triangle-shaped structure between the transition of the ureters in the bladder wall cranially
and the transition of the urethra into the bladder wall caudally [9] (Fig 1).
Endpoints
Side effects were assessed prospectively using questionnaires filled out by patients treated
between 2005 and 2009. The questionnaires have been previously used in a multicenter ran-
domized phase III trial [10] and at our institute [11]. Using these questionnaires, the different
endpoints were scored according to the Common Terminology Criteria for Adverse Events
version 3.0 (CTCAE 3.0) scoring system [12]. Late toxicity was assessed at six months, 12
months, 24 months and 36 months after treatment, finally resulting in a single maximum
Fig 1. Sagittal view of the bladder (red), bladderwall (purple), trigone (orange), prostate (green), anorectum (yellow).
https://doi.org/10.1371/journal.pone.0197757.g001
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toxicity score per endpoint over the entire three years. The minimal follow up of patients alive
was 3 years.
Urinary incontinence grade 2 was defined as spontaneous loss of urine and when use of
pads was indicated. Hematuria grade 1 was defined as minimal bleeding when no intervention
was indicated, while hematuria grade 2 was defined as bleeding requiring medical interven-
tion. Pain or discomfort during urinating grade 1 was defined as mild pain not interfering
with function, while pain grade2 was defined as pain interfering with instrumental activities
of daily living (ADL). Finally, voiding frequency increase was defined as an increase of>2
times normal (grade2).
Statistical analysis
The candidate prognostic factors of the four endpoints in our analysis were selected based on
available literature on GU-NTCP modeling [4–6] and included the mean dose for each organ
at risk and the relative volumes receiving 5–70 Gy, in 5 Gy bins (V5-V70). Additionally, we
included age, adjuvant hormonal treatment, and pre-treatment factors (Table 1) as candidate
predictors, which were retrieved retrospectively from the patient charts.
To show the crude effect of each endpoint, a univariable logistic regression analysis was per-
formed on every endpoint. For the development of the multivariable prediction models the
least absolute shrinkage and selection operator (LASSO) method in R was used, available in
the Lasso and Elastic-Net Regularized Generalized Linear Model package, version 2.0–2 [13].
This is a logistic regression analysis with a penalty for the magnitude of the regression coeffi-
cients to prevent overfitting [14]. Because of the high collinearity of the candidate predictors,
the set of variables was reduced prior to the LASSO analysis; from the dose variables that had
an intercorrelation > 0.80 only the most significant predictor (as measured by the p-value in
univariable analysis) remained a candidate prognostic factor.
Subsequently, the variables selected by LASSO were fitted again to the data with logistic
regression and internally validated through bootstrapping. This validation gives a measure of
optimism of the model, which can be used to correct the coefficients of the model performance
accordingly. Model performance was described using various validation measures [15] [16].
The discriminating ability of the model was described by the Area Under the receiver operat-
ing characteristic Curve (AUC). Nagelkerke’s R2 was calculated as a pseudo measure of
explained variance. The gain and intercept of the model calibration were calculated, and the
calibration was evaluated using a Hosmer-Lemeshow test [17]. Results with p<0.05 were con-
sidered as significant.
Finally, for each endpoint a NTCP curve was constructed based on the corrected regression







Twenty nine out of 243 patients (12.0%) experienced grade 2 or higher urinary incontinence.
The candidate predictors of urinary incontinence included dosimetric predictors of all bladder
structures and pre-treatment variables diabetes, age, cardiovascular disease, abdominal sur-
gery, adjuvant hormonal treatment and TURP. Nine patients experienced grade 2 inconti-
nence prior to radiotherapy. As these patients already experienced the endpoint of the model
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before treatment, they were excluded from the multivariable model on incontinence. In the
univariable analysis and the V55-V75 and mean dose of the trigone were associated with uri-
nary incontinence (Table 2).
The final multivariable analysis resulted in a model with one predictor (Fig 2), i.e. the tri-
gone mean dose (Confidence Interval (CI) Odds Ratio (OR): 1.02–1.20), with a corrected
AUC of 0.66 (CI: 0.58–0.78) and a corrected R-square of 0.10 (Table 3).
In individual cases, the risk of urinary incontinence can be estimated using formula 1,
where S is defined as:
S ¼   9:67þ 0:1015  ðtrigone ðmeanÞÞ
The Hosmer-Lemeshow test was not significant (chi square of 4.91.71; degrees of freedom
(df) = 8; p = 0.77), indicating good agreement between expected and observed complication
rates.
Table 2. Univariable logistic regression analysis for urinary incontinence, hematuria and pain during voiding. Only p-values< 0.05 are shown.
Odds ratio (OR) CI p-Value
Urinary Incontinence  grade 2 (n = 20)
Trigone Mean dose 1.11 1.02–1.20 0.015
V55 1.08 1.01–1.16 0.027
V60 1.06 1.01–1.11 0.016
V65 1.05 1.01–1.08 0.010
V70 1.03 1.01–1.05 0.008
V75 1.01 1.00–1.02 0.042
Hematuria 1 (n = 23)
Cardiovascular disease 2.845 1.19–6.80 0.019
Anticoagulants use 2.424 1.01–5.85 0.049
Bladderwall Mean dose 1.028 1.00–1.06 0.032
V40 1.017 1.00–1.03 0.040
V45 1.019 1.00–1.04 0.024
V50 1.020 1.00–1.04 0.015
V55 1.021 1.00–1.04 0.014
V60 1.022 1.01–1.04 0.011
V65 1.024 1.01–1.04 0.007
V70 1.026 1.01–1.04 0.004
V75 1.027 1.01–1.04 0.002
Bladder V70 1.015 1.00–1.03 0.029
V75 1.015 1.00–1.03 0.021
Pain during voiding
TURP 2.46 1.01–5.99 0.048
Trigone Mean dose 1.106 1.03–1.19 0.008
V50 1.048 1.00–1.10 0.043
V55 1.047 1.01–1.09 0.024
V60 1.042 1.01–1.08 0.015
V65 1.038 1.01–1.07 0.008
V70 1.030 1.01–1.05 0.003
V75 1.021 1.01–1.03 0.001
For dose variables OR: increase per 1 Gy increase in dose, for volume parameters: increase per 1% increase in volume
TURP: transurethral resection of the prostate
https://doi.org/10.1371/journal.pone.0197757.t002
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Fig 2. Final logistic regression analysis for urinary incontinence, hematuria and pain/discomfort during voiding. The left
graphs represent relative volumes with corresponding NTCP risk. The right graphs represent calibration plots for internal validation.
The blue points represent the Hosmer–Lemeshow groups and the dashed line represents the identity line.
https://doi.org/10.1371/journal.pone.0197757.g002
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Hematuria
In total, 23 out of 243 (9.5%) patients experienced grade 1 hematuria, of which 3 (1%) grade
2. Because of the low number of patients with grade 2 toxicity (3), we decided to use grade 1
hematuria as primary endpoint for this analysis. The candidate predictors for hematuria
included dosimetric predictors of all bladder (sub)structures and other pre-treatment vari-
ables, including diabetes, age, cardiovascular disease, abdominal surgery, adjuvant hormonal
treatment, anticoagulants and TURP.
In the univariable analysis grade 1 hematuria was associated with the V40-V75 and mean
dose of the bladder wall and the V70-V75 of the bladder (Table 2). In addition, significant
associations were found with cardiovascular disease and anticoagulant use.
The final multivariable analysis resulted in a model with two predictors (Fig 2), including
the bladder wall V75 (CI OR 1.03–1.03) and cardiovascular disease (CI 3.12–3.31), with a cor-
rected AUC of 0.71 (CI: 0.62–0.84) and a corrected R-square of 0.10 (Table 3). In individual
cases, the risk of hematuria can be estimated using formula 1, where S is defined as:
S ¼   3:45þ 0:028  ðbladderwallðV75ÞÞ þ 1:15  ðcardiovascular diseaseÞÞ
With bladder wall(V75) in relative volume % and cardiovascular disease is 1 (yes) or 0 (no).
The Hosmer-Lemeshow test had a chi square of 4.96 (df = 8, p = 0.76), indicating good
agreement between expected and observed complication rates.
Pain or discomfort during voiding
A total number of 24 out of 243 patients (9.9%) experienced moderate discomfort or pain
during voiding ( grade 2). The candidate predictors of pain or discomfort during voiding
included dosimetric predictors of all bladder (sub)structures and a number of other pre-treat-
ment variables including diabetes, age, cardiovascular disease, abdominal surgery, adjuvant
hormonal treatment and TURP.
In the univariable analysis the V50-V75, mean dose of the trigone and TURP were signifi-
cantly associated with increased pain or discomfort during voiding (Table 2).
The final multivariable analysis resulted in a model with two predictors (Fig 2), including
TURP (CI OR 1.18–7.83) and trigone (V75) (CI OR 1.01–1.04), with a corrected AUC of 0.76
(CI: 0.67–0.86) and a corrected R-square of 0.13 (Table 3). In individual cases, the risk of pain
or discomfort during voiding can be estimated using formula 1, where S is defined as:
S ¼   3:87þ 0:021  ðtrigoneðV75Þ þ 1:06  ðTURPÞ
With trigone(V75) in relative volume % and TURP is 1 (yes) or 0 (no).
The Hosmer-Lemeshow test was not significant (chi square 7.84; df 8; p = 0.48), indicating
good agreement between expected and observed complication rates.
Table 3. Performance and calibration measures for the multivariable model for urinary incontinence, hematuria and pain during voiding. Apparent measures were
calculated using the complete dataset on which the model was trained; the corrected measures were adjusted for optimism as calculated with a bootstrapping procedure.
Performance and calibration measure Urinary incontinence Hematuria Pain during voiding
Apparent Corrected Apparent Corrected Apparent Corrected
AUC 0.66 0.66 0.72 0.71 0.77 0.76
Nagelkerkes R2 0.11 0.10 0.13 0.10 0.16 0.13
Discrimination Slope 0.04 0.04 0.08 0.08 0.08 0.08
AUC: Area under the Curve.
https://doi.org/10.1371/journal.pone.0197757.t003
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Increase in voiding frequency (night and day)
In the univariable and multivariable analysis no significant associations were found for any of
the dosimetric or pre-treatment predictors with voiding frequency.
Discussion
The main objective of this study was to develop multivariable NTCP models for urinary incon-
tinence, hematuria, pain or discomfort during voiding and increase in voiding frequency
based on different subregions within the bladder. Urinary incontinence was best predicted by
the trigone mean dose. Hematuria was best predicted by the bladder wall V75 and cardiovas-
cular disease. Pain or discomfort during voiding was best predicted by the trigone V75 and
cardiovascular disease. No associations were found for increase in voiding frequency.
Our data show that the dose to the trigone may have an impact on the occurrence of GU
complaints, which is in line with research on patients with high-dose IMRT (86.4 Gy) [9] and
with brachytherapy [6,7]. In both studies complaints were scored using the IPSS (International
Prostate Symptom Score (IPSS)), resulting in a single (side effect) score for each patient. As
different GU side effects have a different pathophysiology [18], relating each side effect indi-
vidually to different dose parameters may be more appropriate and results in more appropriate
associations between dose-volume parameters and specific side effects.
Urinary incontinence may originate in the trigone of the bladder, as the lower part contains
the involuntary internal or pre-prostatic sphincter [18]. A decrease in dose to this region may
likely decrease the incidence of urinary incontinence. However, the external sphincter of the
bladder may also play a role in urinary incontinence as it controls the voluntary control of
voiding. The external sphincter lies directly beneath the prostate and thereby receives high
doses. As this structure is hard to distinguish on CT images we were not able to investigate the
impact of dose to this region. The use of MRI in delineating target organs may offer better
opportunities to analyze the effect of external sphincter dose-volume parameters on inconti-
nence, as the external sphincter can be better identified with MRI [18].
External beam radiotherapy can cause hematuria [19–20], which is most likely related to
the high dose areas within the bladder [21]. In the latter study the volume of the whole bladder
receiving 75 Gy was the best predictor for hematuria. Although the univariable analysis of
the present study showed similar results, no such relationship was found in the final multivari-
able model, which actually showed that the dose to the bladder wall was a better predictor of
hematuria than the entire bladder dose. These results suggest that the dose to the entire blad-
der is a surrogate for the importance of the dose to the bladder wall. From a pathophysiological
point of view, it seems evident that dose hotspots to the bladder wall are more indicative of
side effects [22–23]. Anticoagulants use was significantly related to hematuria in the univari-
able analysis, which is in accordance with a study by Palorini [24]. In that study, cardiovascular
drugs were found as risk factors for a decreased IPSS score, indicating a possible impaired
healing process of radiation-induced damage in patients with microangiopathic disease. Inter-
estingly, anticoagulants were not significant anymore in our multivariable model. This may be
caused by the fact that a significant number of patients with cardiovascular disease used anti-
coagulants. Cardiovascular disease NTCP models performed better than NTCP models with
anticoagulants, indicating the importance of taking into account cardiovascular disease in
treatment of prostate cancer patients [25–26].
The question may arise what the impact is of volume and motion of the bladder on finding
dose-volume relations. A study by Palorini [27] on bladder motility during treatment showed
that the cranial and anterior part of the bladder exhibits large systematic variation. The caudal
part of the bladder however is relatively independent of bladder filling and may therefore be a
Prediction of side effects after prostate radiotherapy
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reliable predictor in optimizing prostate radiotherapy. The trigone is a relatively rigid part of
the bladder, as the bladder neck is surrounded by the prostate and encompassing pubopro-
static ligaments [28]. A study on prostatectomy shows that sparing of these ligaments may
result in less urinary incontinence [29]. Taking these results into account, the dose to the tri-
gone that we found to be predictive of urinary incontinence and pain, may be a surrogate for
these ligaments. However, these ligaments were not visible on CT and were therefore not
investigated as an organ at risk for any of the four endpoints.
Although increase in voiding frequency is reported frequently as a side effect resulting from
prostate radiotherapy, we were not able to find an association between dose to different ana-
tomical regions and increase in voiding frequency. In a recent study using a pixel-wise analysis
of dose-surface maps [30], a relation was found between the dose to the posterior bladder at
5–12 mm from the base and an acute increase in voiding frequency. Therefore, future research
should focus on this endpoint to confirm this dose-volume relation in order to prevent a
decrease in quality of life of prostate cancer patients.
A limitation of this study was the low number of events for each endpoint. The internal vali-
dation showed that for these data the models performed relatively well and despite the low
number of events the robustness in this dataset was relatively large [3] [31]. There are different
ways to analyze dose-effect relationships, e.g. LASSO, bootstrapping and “simple” backward
regression analysis. To check the robustness of our analysis, all of the aforementioned proce-
dures were tested in our data and all led to more or less the same results, indicating our results
were relatively independent of the type of analysis that was used and relatively independent of
the low number of events. However, external validation in other datasets is warranted. We are
currently working on a study to validate our data externally as was done at our institute for
head and neck cancer patients [32].
Another limitation of this study is the variability of the bladder volume during treatment.
Research has shown that patient motion, bladder centroid motion and bladder filling may
have an impact on pretreatment imaging [33]. We recommend researchers to take this into
account in future studies on prostate NTCP-modeling by using daily imaging techniques and
deformable image registration.
This study shows that different anatomical subregions within the bladder are related to dif-
ferent side effects. Urinary incontinence and pain during voiding is related to dose to the tri-
gone and hematuria is related to the dose in the bladder wall. This information can be used in
treatment plan optimization. Additional prospective studies are needed to confirm that dose
reductions to these regions result in less side effects.
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